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Side effects of antidepressants are usually underreported in clinical trials and large scale
naturalistic studies are restricted to six months of use. We examined the prevalence and nature
of patient-perceived side effects and their determinants during long-term antidepressant use in
a naturalistic setting. Subjects, aged 19 to 67 years, in the Netherlands Study of Depression and
Anxiety were recruited from primary care and specialized mental health care covered 927 cases
of single antidepressant use. In 64% of cases, on average, 2.9 side effects were reported.
The number of side effects was higher when subjects had higher depression severity (OR=1.28;
p=0.002), three or more psychiatric diagnoses (OR=1.97; p=0.02), higher dose (OR=1.44;
p=0.006) and was lower when subjects were older (OR=0.83; p=0.02) and had longer duration
of use (OR=0.94; p=0.04). Tricyclic antidepressants were associated with more side effects
(OR=2.52; p=0.003) and, particularly, more anticholinergic effects, like dry mouth and
constipation, as compared to selective serotonin reuptake inhibitors. Venlafaxine showed more
profuse sweating (OR=1.79; p=0.007), whereas mirtazapine showed more weight gain and less
sexual dysfunction (OR=0.36; p=0.03), as compared to selective serotonin reuptake inhibitors.
Weight gain was associated with female gender (OR=1.76; p=0.004) and duration of use
(OR=1.06; p=0.03). We show that antidepressant side effect, known from short-term studies,
persist during long-term use and are associated with depression severity and antidepressant dose.Elsevier B.V. and ECNP. All rights reserved.
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P.M. Bet et al.1444A novel finding was that venlafaxine is associated with more profuse sweating and that weight gain
appeared more specific in female users. Clinicians should be aware that, during long-term
antidepressant use, side effects are common and persistent.
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Antidepressant use is associated with a variety of side effects
(SEs). In clinical trials their prevalence is up to 27% (Trindade
et al., 1998). SEs interfere with optimal treatment dosages
and may be the cause of medication non-adherence and
discontinuation (Lingam and Scott, 2002). Although SEs should
be known before an antidepressant is introduced in daily
practice, SE assessment in clinical trials concerning mental
health is inadequate, particularly with respect to long-term
effects (Papanikolaou et al., 2004). A recent large scale meta-
analysis of 143 clinical trials on antidepressants showed that
structured and systematic SE assessment strategies were used
in only 21% of these trials (Rief et al., 2009). Moreover,
a systematic review on 115 studies revealed that only a few
trials used an objective side effect rating scale whereas
adverse events were rarely pre-specified and defined
(Gartlehner et al., 2008). In clinical trials often only short-
term severe SEs are reported. This lack of adequate SE data is
hindering the evaluation of antidepressant risk–benefit ratios
(Papanikolaou et al., 2004).
Although participants of antidepressant clinical trials
represent only a small highly selected minority of depressed
patients in clinical practice, trial results on efficacy can be
generalized to the general population (van der Lem et al.,
2011; Zimmerman et al., 2002). Clinical trials have revealed
differences in SE profiles among different types of anti-
depressants (Anderson, 2000; Trindade et al., 1998;
Watanabe et al., 2010; Stahl et al., 2005; Gartlehner
et al., 2008). However, it is not clear whether there is
similarity between SEs reported in clinical trials and those
occurring in daily practice (van der Lem et al., 2011;
Zimmerman et al., 2002). Prescription Event Monitoring
has provided naturalistic SE data in a primary care setting
of short-term (up to 6 months) antidepressant use (Mackay
et al., 1997; Mann et al., 1997; Mackay et al., 1999), but
antidepressant-induced SE data in a long-term naturalistic
setting is lacking.
Little is known about the persistence of patient-
perceived SEs during long-term antidepressant use. In a
large short-term study comparing citalopram and nortripty-
line most SEs, which were assessed on a weekly basis,
decreased over a 12 week study period (Uher et al., 2009).
The clinical notion that SEs wear off during prolonged use
over years is not substantiated with data. The mean
incidence of headache and nausea in 27 antidepressant
continuation- and maintenance-phase studies was 16% and
7%, respectively. Compared to acute phase studies, the
relative incidence of these events was only slightly lower
(Hansen et al., 2008). Finally, reports of long-term clinical
trials also seldom provide differentiation between SE pre-
valence at the beginning of the trial and SE prevalence after
6–24 months of continued treatment (Kasper et al., 2008;
Thase et al., 2011).Patient-, disease- and treatment-related factors like age
(Draper and Berman, 2008; Naranjo et al., 1995; Stone et al.,
2009), depression severity (Wilting et al., 2009; Uher et al.,
2009) and type and dose of antidepressant (Trindade et al.,
1998; Watanabe et al., 2010; Stahl et al., 2005) influence the
occurrence and severity of SEs in clinical trials. Because of
unknown external validity of SE data from clinical trials to
long-term daily use and the lack of systematic SE data
comparing different antidepressants over an extended time
course, it is important to study antidepressant-induced SEs
during long-term use in a naturalistic setting. We therefore
examined the prevalence, nature and determinants of SEs
during long-term use of different types of antidepressants in a
naturalistic setting.
2. Experimental procedures
2.1. Study sample
All subjects participating in the present study came from the
Netherlands Study of Depression and Anxiety (NESDA), an ongoing
longitudinal cohort study conducted among 2981 adult subjects
(18–65 years) to examine (predictors of) the long-term course of
depression and anxiety disorders. The rationales, methods and
recruitment strategy have been described elsewhere (Penninx
et al., 2008).
The NESDA sample consists of 652 persons without depression or
anxiety disorders and 2329 with a (remitted or current) diagnosis of
a depressive and/or anxiety disorder. In order to represent various
settings and stages of psychopathology, depressed or anxious
subjects were recruited at three different locations in the Nether-
lands in different settings: community, primary care, and specia-
lized mental health care. Community-based subjects were
previously identified in two population-based studies (Nemesis and
Ariadne). Primary care subjects were identified through a 2-stage
screening procedure (involving the K10 questionnaire (Kessler
et al., 2002; Kessler et al., 2003) and the CIDI-SF [Composite
International Diagnostic Interview, Short Form] telephone inter-
view) conducted among patients of 65 general practitioners. Mental
health care patients were recruited when newly admitted to one of
the 17 participating mental health organizations. Subjects with
clinically overt psychotic disorder, obsessive compulsive disorder,
bipolar disorder, or severe addiction disorder were excluded. The
study protocol was approved centrally by the Ethical Review Board
of the VU University Medical Center and subsequently by local
review boards of each participating center. All subjects signed an
informed consent at baseline assessment.
NESDA subjects were enrolled between September 2004 and
February 2007. One-year follow-up data were acquired by means of
a written questionnaire (n=2445) and the two-year follow up data
were obtained by means of a face to face interview (n=2596).
All subjects who reported using antidepressants or did so in the
year preceding the first (1-year) and/or second (2-year) follow-up,
were included in the study sample (n=907). If subjects reported the
same antidepressant at both assessments, we used the first assess-
ment and excluded the second assessment in order not to bias the
prevalence of side effects. Subjects using two antidepressants at
1445Side effects of antidepressantsthe same time (n=61) were excluded in order to avoid attribution
of SEs to the wrong antidepressant. Eighty one subjects reported
two different episodes of single antidepressant use. Therefore,
our study sample consisted of 927 cases of antidepressant use
within 846 subjects. Six hundred and twenty five cases originated
from the one-year follow-up data and 302 cases from the two-year
follow-up. Seventy six percent of the cases (n=701) reported SEs on
current use, the others reported SEs while not currently on
medication anymore. All data was obtained at the time of the SE
assessment.2.2. Medication use
Current medication use including name, dose end daily amount of
both psychotropic and non-psychotropic medication, was inventor-
ied with the aid of the subjects' medication boxes. Medication use
was checked whether the information provided was pharmaceuti-
cally possible. Duration of use of the antidepressant on which SEs
were reported, was noted in months. We classified medications by
using the World Health Organization Anatomical Therapeutic Che-
mical (ATC) system (WHO, 2012). We distinguished selective ser-
otonin re-uptake inhibitors (SSRIs, ATC code N06AB), tricyclic
antidepressants (TCAs, ATC code N06AA), venlafaxine (ATC code
N06AX16), mirtazapine (ATC code N06AX11) and other antidepres-
sants (including monoamine oxidase inhibitors, non-selective N06AF
and antidepressants classified as N06AX, excluding N06AX11 and
N06AX16). For all antidepressants a derived daily dose was calcu-
lated by dividing the subject's daily dose used by the defined daily
dose (DDD) recommended by the WHO (WHO, 2012). Benzodiaze-
pine use was determined by selecting ATC codes N03AE, N05BA,
N05CD and N05CF.2.3. Side effects
SEs were collected for every psychotropic drug, including alter-
native medicines like St John's wort, the subject used on a daily
basis and for all psychotropic medication used in the last year.
A short 12-question self-report Antidepressant Side Effect Checklist
(ASEC-12) was constructed. Recently, the self-report ASEC-21 was
validated (Uher et al., 2009) against the UKU Side Effect Rating
Scale, a semistructured interview by a health professional
(Lingjaerde et al., 1987). The ASEC-12 shortlist specifically asks
for the presence of patient-perceived SEs, related to antidepres-
sant therapy: insomnia, sleepiness during the day, restlessness,
muscle spasms/twitching, dry mouth, profuse sweating, sexual
disorders, nausea, constipation, diarrhea, weight gain and dizzi-
ness. We did not define a specific time period in which the SEs
should have occurred and expect to measure current side effects or
side effects that have occurred recently.2.4. Psychiatric status
The presence of depressive and anxiety disorders in the preceding
two years was assessed using the CIDI 2.1 psychiatric interview. The
presence or absence of a major depressive disorder, minor depres-
sive disorder, dysthymia, panic disorder (with or without agorapho-
bia), social phobia or generalized anxiety disorder was also
assessed. The CIDI establishes diagnoses according to DSM-IV
criteria (American Psychiatric Association, 2001) and has shown
high inter-rater and test–retest reliability and high validity for
depressive disorders (Wittchen, 1994). The severity of depression
was evaluated using the 30-item Inventory of Depressive Symptoms
self-report version (IDS-SR), which also includes various anxiety
items (Rush et al., 1996). Alcohol dependence and alcohol abuse
was assessed with the CIDI interview.2.5. Statistical analyses
SE parameters were compared in the four groups of antidepres-
sants, being SSRI, TCA, venlafaxine and mirtazapine (n=884),
excluding ‘St John's wort’ and ‘other antidepressants’. The number
of SEs per case were divided in three categories: ‘no SEs’, ‘one or
two SEs’ and ‘three or more SEs’. Overall p-values were calculated
using χ2-statistics for the categories of the number of SEs and the
presence of specific SEs. The four groups of antidepressants were
individually compared with univariate analyses using χ2-statistics.
P-value cut-offs of 0.05 were considered as significant.
In a multivariate analysis we included subject-related factors
(gender, age, years of education), disease related factors (depres-
sion symptom severity, number of psychiatric diagnoses and benzo-
diazepine use) and antidepressant-related factors (type of
antidepressant, dose and duration). The number of SEs, divided
into the three categories, were analyzed using multinomial logistic
regression analysis. Multivariate logistic regression analyses were
used for the presence of SEs with a prevalence of 10% or higher.
Data were analyzed using SPSS 15.0.3. Results
Demographics and basic characteristics of the 846 subjects are
presented in Table 1. Their mean age was 43.0 years and 67%
was female. Thirty eight percent of the 927 cases had a
co-morbid depression and anxiety disorder and 31% used a
benzodiazepine. SSRI use (63%) mainly concerned paroxetine,
fluoxetine, citalopram and escitalopram. TCA use included
amitriptyline, nortriptyline and clomipramine. In 2.6% of the
cases St John's wort was used.
In 64% of cases of antidepressant use, on average 2.9 SEs
were reported. Absence of SEs was more common with SSRI
use, as compared to venlafaxine use (p=0.03) and, although
not significantly, compared with TCA use (p=0.10)
(Table 2). No SEs were reported for alternative treatment
with St John's wort.
The average prevalence of specific SEs ranged from 6% to
25%. As compared to SSRIs, TCAs caused more typical
anticholinergic SEs like constipation and dry mouth.
As compared to SSRIs, the use of venlafaxine was associated
with more muscle spasms/twitching, profuse sweating,
sexual dysfunction and dizziness. Mirtazapine was asso-
ciated with more sleepiness during the day and but less
constipation and sexual dysfunction. In this univariate
analysis we did not find a clear positive association between
mirtazapine use and weight gain as compared to SSRIs.3.1. Determinants of SEs in multivariate analyses
SE reporting was associated with depression severity and
additional psychiatric diagnoses, TCA use and higher
dosages. SE reporting was negatively associated with age,
concurrent use of benzodiazepines and prolonged antide-
pressant use (Table 3). Analyses of comparing ‘one or two
SEs’ and ‘three or more SEs’ vs. reporting ‘no SEs’ show
consistency in the directions of these associations. Except
for years of education, the analysis of ‘three or more SEs’
showed stronger associations.
In contrast with the univariate analysis, the use of TCAs
was independently associated with more reporting of ‘one
Table 1 Baseline characteristics of antidepressant
users (n=846) and cases of antidepressant use (n=927).
Number of antidepressant users n=846
Sociodemographics
Gender (% Female) 67
Age (mean in years, SD) 43 (12)
Years of education (mean in years, SD) 12 (3.3)
Number of cases of antidepressant use n=927a
Psychiatric status
MDD and Anxiety disorders (%) 38
MDD alone (%) 22
Anxiety disorders alone (%) 12
No current diagnosis (%) 28
Number of psychiatric diagnosis (mean, SD) 1.8 (1.5)
Depression severity (mean IDS score, SD) 24 (13)
Concurrent benzodiazepine use (%) 31
Alcohol dependence (%) 10.2
Alcohol abuse (%) 8.8
Antidepressant characteristics
Selective serotonine reuptake inhibitors
(%)
63.0
Tricyclic antidepressants (%) 10.5
Venlafaxine (%) 15.6
Mirtazapine (%) 6.3
St John's wort (%) 2,6
Other antidepressants (%) 2.0
Dose (median (IQR 25%–75%)b,
in Defined Daily Dose)
1.0
(1.0–1.5)
Duration of use (median (IQR 25%–75%)b,
in years)
1.0
(0.4–2.0)
a81 subjects have reported on two different episodes of
antidepressant use.
bIQR 25%–75%= interquartile range.
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Venlafaxine and mirtazapine did not show this difference.
Although females did not report more SEs, female gender
was associated with more constipation and weight gain and
with less sexual dysfunction (Table 4). Higher age was
associated with less sleepiness during the day, less profuse
sweating and less dizziness. Depression severity was asso-
ciated with dizziness and anticholinergic SEs like constipa-
tion and dry mouth.
TCAs were associated with more anticholinergic SEs
compared with SSRIs. Venlafaxine only differed from SSRIs
in its association with more profuse sweating. Concurrent
benzodiazepine use was associated with less profuse sweat-
ing. Compared with SSRIs, mirtazapine showed less sexual
dysfunction and more weight gain. The dose of the anti-
depressant was associated with increased odds for most
specific SEs with odds ratios between 1.1 and 1.5.
4. Discussion
This naturalistic study shows that patient-perceived SEs are
common and persist during long-term antidepressant use ina large cohort of patients with depression and/or anxiety
disorders. Our structured inventory of 12 common antide-
pressant SEs confirms the known differences in SE profiles
among different types of antidepressants. However, it also
shows venlafaxine to be associated with more profuse
sweating compared with SSRIs. The number of reported
SEs is higher at younger patient age, higher depression
severity, more psychiatric diagnoses, higher antidepressant
dose and shorter duration of use. Weight gain is associated
with female gender and longer duration of use. Other
specific SEs are associated with antidepressant dose and/or
depression severity.
Our multivariate model (Table 3) indicates that SEs are more
common with TCAs as compared to SSRI, whereas this differ-
ence is not shown for venlafaxine and mirtazapine. This is in
line with a meta-analysis of many short-term clinical trials,
where TCAs had inferior tolerability compared with SSRIs
(Anderson, 2000). A meta-analysis of clinical trial data shows
venlafaxine to be more efficacious and have more SEs com-
pared with SSRIs (Schueler et al., 2011). Short-term prescrip-
tion event monitoring in primary care setting shows no major
differences in SE reporting (Mackay et al., 1999). In long-term
use we now find no difference in the number of reported SEs
between SSRI and venlafaxine. This is shown in a multivariate
model, that includes the dose of the antidepressant. Hereby,
we provide an intrinsic comparison between the types of
antidepressants independent of the dose. This could provide
an explanation for the differences found in clinical trials,
where high dosages of venlafaxine were used to provide higher
efficacy at the cost of decreased tolerability as compared to
SSRIs (Schueler et al., 2011). In multivariate analysis, mirtaza-
pine showed less sexual dysfunction and more weight gain
when compared with SSRIs in long-term use. These are two
important features of mirtazapine, which have previously been
demonstrated in short-term studies (Watanabe et al., 2010).
In several long-term studies of Hypericum extracts
(Kasper et al., 2010; Kasper et al., 2008), placebo level
SEs are reported. We did not have a single report of SEs on
the use of St John's wort preparations, but this could be due
to the fact that these preparations were not licensed at the
time of data collection and detailed information on
preparation strengths and dosages used was not available.
This alternative treatment was not prescribed by medical
doctors and were only taken on the patient's own instiga-
tion, possibly resulting in easy discontinuation of treatment
in case of side effects. In addition, the number of John's
wort users in this sample was very small, limiting the
interpretation of our findings regarding this sample.
In a short-term study, detailed information on the
time course of SEs of escitalopram and nortriptyline has
been published (Uher et al., 2009). Prevalence of drowsi-
ness, headache, nausea and orthostatic dizziness dropped,
whereas other SEs, particularly anticholinergic SEs and
sexual dysfunction, persisted over the 12-week treatment
course. In the present study we find slightly lower SE
reporting with prolonged antidepressant use, while no
associations are detected between specific SEs and pro-
longed use. During long-term antidepressant use, all specific
SEs seem to persist.
In univariate analyses, anticholinergic SEs, like dry mouth
and constipation, were reported more often with TCA
use, compared with all other types of antidepressants.
Table 2 Prevalence of side effects (SEs in %) to different types of antidepressant (n=927).
Type of antidepressant SSRI
n=584
TCA
n=97
VEN
n=145
MIR
n=58
Overall
p-value
SJW
n=24
Other ADs
n=19
Number of SEs per case
Zero SEs (%) 36a 28 27a 36 0.09 100 47
One or two SEs (%) 33 33 37 40 0.55 0 26
Three or more SEs (%) 31 39 36 24 0.16 0 26
Type of SE
Sleeplessness (%) 7 5 10 5 0.50 0 16
Sleepiness during the day (%) 21 14a 20 30a 0.16 0 16
Restlessness (%) 9 6 10 12 0.64 0 11
Muscle spasms, twitching (%) 9a 12 15a 7 0.09 0 5
Dry mouth (%) 22a 49a,b,c 23b 22c o0.001e 0 16
Profuse sweating (%) 20a 20b 32a,b,c 14c 0.01e 0 11
Sexual dysfunction (%) 23a,b 20c 31a,c,d 10b,d 0.01e 0 11
Nausea (%) 10 4 9 5 0.16 0 11
Constipation (%) 8a 20a,b,c 10b,d 2c,d 0.001e 0 0
Diarrhea (%) 7 4 5 5 0.58 0 0
Weight gain (%) 19 22 17 29 0.24 0 16
Dizziness (%) 12a 11 19a 12 0.15 0 5
AD=antidepressant, SE=side effect, SSRI=selective serotonine reuptake inhibitor, TCA=Tricyclic Antidepressant, VEN=Venlafaxine,
MIR=Mirtazapine, SJW=St John's wort.
a,b,c,dDifference in SE prevalence between two types of AD in univariate analysis, po0.05.
eDifference in SE prevalence between SSRI, TCA, venlafaxine and mirtazapine, overall p-value o0.05.
Table 3 Adjusted odds ratios (95%CI) of multivariate analysis examining determinants to SE reporting (n=884).
One or two SEs (vs. no SEs) Three or more SEs (vs. no SEs)
OR (95%CI)a p OR (95%CI)a p
Female (vs. male) 0.69 (0.48–0.99) 0.05 0.94 (0.64–1.37) 0.74
Age (per 10 years increase) 0.86 (0.74–1.00) 0.06 0.83 (0.71–0.97) 0.02
Years of education (per year increase) 1.06 (1.00–1.12) 0.04 1.03 (0.97–1.08) 0.39
Depression severity (per 10 points increase) 0.94 (0.80–1.11) 0.48 1.28 (1.09–1.51) 0.002
Number of psychiatric diagnosis
No diagnosis Ref – Ref –
One or two 0.98 (0.64–1.50) 0.93 1.31 (0.82–2.08) 0.26
Three or more 1.66 (0.98–2.81) 0.06 1.97 (1.14–3.41) 0.02
Concurrent benzodiazepine use 0.73 (0.49–1.06) 0.10 0.64 (0.43–0.94) 0.02
Type of antidepressant
SSRI Ref – Ref –
TCA 2.02 (1.10–3.68) 0.02 2.52 (1.39–4.60) 0.003
Venlafaxine 1.60 (0.98–2.60) 0.06 1.39 (0.84–2.28) 0.20
Mirtazapine 1.42 (0.73–2.77) 0.30 0.93 (0.44–1.96) 0.84
Dose 1.09 (0.83–1.43) 0.54 1.44 (1.11–1.85) 0.006
Duration of use (per year increase) 0.97 (0.92–1.02) 0.22 0.94 (0.89–1.00) 0.04
aBased on multinomial logistic regression analysis, adjusted for type of antidepressant (excluding ‘St John's wort’ and ‘other
antidepressants’), dose, duration of antidepressant use, gender, age, education, depression severity and number of psychiatric
diagnosis.
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associated with increased odds on overall SEs and specific
SEs. These findings are well known from clinical trials and
are therefore important markers of the validity of our
findings in a naturalistic setting.Elderly people generally are more sensitive to the toxic
effects of psychotropic medication (Naranjo et al., 1995).
In this patient group particular attention goes to the risk
of adverse outcomes, like falls, fractures, upper gastro-
intestinal bleeding, epilepsy/seizures and hyponatremia
Table 4 Adjusted odds ratios (95%CI) of multivariate analysis examining determinants to specific SEs (n=884).
Sleepiness during the day Muscle spasms/twitching Dry mouth Profuse sweating
Prevalence 20% OR (95%CI)a p 20% OR (95%CI)a p 25% OR (95%CI)a p 22% OR (95%CI)a p
Female (vs. male) 0.83 (0.58–1.18) 0.30 0.97 (0.60–1.57) 0.91 1.17 (0.83–1.64) 0.38 0.98 (0.69–1.39) 0.89
Age (per 10 years increase) 0.82 (0.71–0.96) 0.01 0.95 (0.89–1.03) 0.06 0.99 (0.84–1.13) 0.72 0.84 (0.72–0.97) 0.02
Years of education (per year increase) 1.01 (0.96–1.07) 0.68 0.95 (0.89–1.03) 0.19 0.99 (0.95–1.05) 0.82 1.00 (0.95–1.06) 0.93
Depression severity (per 10 points increase) 1.13 (0.97–1.31) 0.11 1.14 (0.94–1.39) 0.17 1.19 (1.03–1.37) 0.02 1.10 (0.95–1.27) 0.22
Number of psychiatric diagnosis
No diagnosis Ref – Ref – Ref – Ref –
One or two 1.50 (0.92–2.45) 0.11 1.26 (0.66–2.41) 0.48 1.09 (0.70–1.70) 0.70 1.08 (0.68–1.69) 0.75
Three or more 1.91 (1.10–3.32) 0.02 1.11 (0.53–2.32) 0.78 1.29 (0.78–2.13) 0.33 1.31 (0.78–1.22) 0.30
Concurrent benzodiazepine use 0.68 (0.46–1.01) 0.05 0.80 (0.48–1.33) 0.39 1.06 (0.75–1.51) 0.73 0.57 (0.39–0.84) 0.005
Type of antidepressant:
SSRI Ref – Ref – Ref – Ref –
TCA 0.81 (0.44–1.52) 0.52 2.01 (0.99–4.07) 0.05 4.00 (2.49–6.43) o0.001 1.36 (0.77–2.39) 0.29
Venlafaxine 0.81 (0.50–1.30) 0.38 1.65 (0.94–2.89) 0.08 0.96 (0.61–1.50) 0.85 1.79 (1.17–2.74) 0.007
Mirtazapine 1.75 (0.93–3.28) 0.08 0.93 (0.32–2.72) 0.89 1.09 (0.56–2.12) 0.80 0.78 (0.35–1.72) 0.53
Dose 1.27 (1.01–1.60) 0.04 1.52 (1.15–2.00) 0.03 1.36 (1.10–1.69) 0.005 1.45 (1.16–1.81) 0.001
Duration of use
(per year increase)
0.98 (0.92–1.04) 0.47 0.94 (0.86–1.03) 0.20 0.97 (0.92–1.02) 0.23 0.98 (0.92–1.03) 0.40
Sexual dysfunction Constipation Weight gain Dizziness
Prevalence 23% OR (95%CI)a p 10% OR (95%CI)a p 20% OR (95%CI)a p 13% OR (95%CI)a p
Female (vs. male) 0.49 (0.35–0.68) o0.001 3.18 (1.71–5.92) o0.001 1.76 (1.19–2.59) 0.004 0.72 (0.47–1.10) 0.13
Age (per 10 years increase) 0.95 (0.82–1.09) 0.45 1.06 (0.86–1.31) 0.59 0.95 (0.81–1.10) 0.49 0.80 (0.66–0.95) 0.01
Years of education (per year increase) 1.01 (0.96–1.06) 0.83 1.11 (1.03–1.19) 0.006 1.01 (0.96–1.07) 0.67 1.00 (0.93–1.06) 0.88
Depression severity (per 10 points increase) 1.02 (0.89–1.18) 0.75 1.38 (1.12–1.69) 0.002 1.08 (0.93–1.26) 0.31 1.47 (1.24–1.75) o0.001
Number of psychiatric diagnosis
No diagnosis Ref – Ref – Ref – Ref –
One or two 1.68 (1.07–2.66) 0.03 1.31 (0.66–2.59) 0.44 0.99 (0.63–1.56) 0.97 1.37 (0.75–2.50) 0.31
Three or more 1.64 (0.96–2.79) 0.07 1.08 (0.49–2.34) 0.86 1.05 (0.62–1.77) 0.87 1.13 (0.57–2.22) 0.73
Concurrent benzodiazepine use 0.76 (0.52–1.09) 0.13 1.04 (0.62–1.74) 0.88 0.88 (0.60–1.29) 0.52 0.75 (0.48–1.19) 0.22
Type of antidepressant:
SSRI Ref – Ref – Ref – Ref –
TCA 0.91 (0.52–1.60) 0.74 3.18 (1.67–6.06) o0.001 1.29 (0.74–2.25) 0.36 1.08 (0.53–2.18) 0.85
Venlafaxine 1.35 (0.89–2.06) 0.16 1.18 (0.62–2.24) 0.61 0.93 (0.57–1.52) 0.77 1.38 (0.83–2.30) 0.21
Mirtazapine 0.36 (0.15–0.88) 0.03 0.22 (0.03–1.65) 0.14 2.32 (1.24–4.35) 0.009 0.99 (0.42–2.34) 0.99
Dose 1.21 (0.97–1.50) 0.10 1.21 (0.89–1.65) 0.23 1.24 (0.98–1.57) 0.07 1.11 (0.85–1.45) 0.45
Duration of use (per year increase) 1.01 (0.96–1.07) 0.69 0.93 (0.85–1.02) 0.11 1.06 (1.01–1.11) 0.03 0.97 (0.90–1.05) 0.43
aAdjusted for type of antidepressant (excluding ‘St John’s wort’ and ‘other antidepressants’), dose, duration of AD use, gender, age, education, depression severity and number of
psychiatric diagnosis.
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ever, looking at patient perceived SEs, in the present study
SE reporting declines with age. Such a negative association
with age is also found for several specific SEs, like sleepiness
during the day, profuse sweating and dizziness. These
results are in line with those obtained for the SSRI citalo-
pram. For a range of specific SEs including headache,
nausea, diarrhea and sweating, younger people of 18–64
years of age reported more SEs than patients older than 65
years (Barak et al., 2003). For serotonergic SEs, like nausea,
diarrhea and sweating, this effect might be caused by the
age-related reduction of sensitivity of the serotonergic
system (Meltzer et al., 1998). However, a cohort study on
short-term SSRI use involving more than 40,000 users, found
no differences in SEs between the elderly (470 years) and
younger patients (o70 years) (Mackay et al., 1997). The
present results on patient-perceived SEs during long-term
use contribute to the on-going debate on the association
between age and SEs.
Both depression severity and an increased number of
psychiatric disorders are associated with increased overall
SE reporting. Depression severity is also positively asso-
ciated with specific SEs, like dry mouth, constipation and
dizziness. The association of depression severity and SE
reporting has been described previously in a short-term
antidepressant trial (Uher et al., 2009) and for long-term
lithium use (Wilting et al., 2009). Uher et al. showed that
this association was not caused by confounding in the
assessment of SEs and depression severity. A mechanism
for perceiving and reporting more SEs by more severely
disease-affected patients could be their increased sensitiv-
ity and attention to physical discomfort as has been
observed with pain perception in depression (Klauenberg
et al., 2008).
A recent meta-analysis showed large differences in
weight gain between individuals as the result of treatment
with various antidepressants (Serretti and Mandelli, 2010).
In the present study female gender and prolonged anti-
depressant use are found to be associated with weight gain.
However, this finding could be biased by the fact that part
of the women might be more dissatisfied with their body
weight and shape when compared to men (Rolls et al., 1991)
and the natural tendency for people to get heavier over the
years. Nevertheless, body weight increase as the result of
antidepressant use should be monitored carefully as it is an
important risk factor for the metabolic syndrome.
Profuse sweating can be very distressing and may cause
impairment in social and occupational functioning. In the
present study substantially more patients using venlafaxine
experienced profuse sweating as compared with SSRI users.
In a recent long-term efficacy study, sweating was reported
in 16% of the patients after 8–20 months of venlafaxine use
at average dosages of 225 mg a day, and 10% of the patients
on fluoxetine at average dosages of 50 mg a day (Thase
et al., 2011). In our study, when specifically asked, profuse
sweating was experienced in 32% of venlafaxine users
and 20% of SSRI users. Due to our large study population
this difference was statically significant both in univariate
as well as multivariate analysis. High antidepressant
dosages were also associated with increased odds for
profuse sweating. This finding supports observations of
SSRI-induced sweating resolving after dose reduction(Marcy and Britton, 2005). In contrast with sweating as a
side effect, low doses venlafaxine and paroxetine are
effective in preventing sweating as a part of the treatment
for vasomotor symptoms in menopausal women (Carroll and
Kelley, 2009). The concurrent use of benzodiazepines was
associated with less profuse sweating. In a small placebo
controlled trial on hyperhydrosis in patients with a social
anxiety disorder clonazepam was as efficacious as fluoxetine
(Davidson et al., 2002). These data suggest that benzodia-
zepines may be helpful when hyperhydrosis triggered by
psychosocial stressors emerges as SE in patients treated
with antidepressants.
A strength of the present study is the use of the NESDA
cohort which provides a large dataset on both clinical
features of depression and anxiety including indicators of
the CIDI diagnosis and severity of symptoms through
validated scales. NESDA incorporates large groups of
severely affected patients both with depression and anxiety
disorders. These groups are often under-represented in
large population-based surveys and in clinical trials. We
used the same self-report structured SE ASEC-12 shortlist for
all types of antidepressants. The assessment of patient-
perceived SEs by self-report has recently been validated
against the psychiatrist rated UKU Side Effect Rating Scale
(Uher et al., 2009). A few limitations need to be discussed.
Because we did not define a specific time period in which
the SEs should have occurred, severe side effects from
earlier times could be measured due to re-call bias. All
participants of the present study were familiar with the
medication they used and were likely informed on possible
SEs, which is known to influence SEs reporting (Rief et al.,
2009). Moreover, due to the naturalistic setting, associa-
tions between SEs and type of antidepressant, dose and
duration may have been weakened by routine clinical
measures like lowering of dosages, switching and disconti-
nuation of the antidepressant. We did not provide data on
preceding antidepressant use. In case of short duration of
antidepressant use, preceding use with an antidepressant
from the same therapeutic class could, in theory, slightly
lower the prevalence of class-specific side effects due to
tolerance.
In conclusion, the present large naturalistic cohort study
shows that during long-term use SEs to antidepressants are
common. Known differences in SE profiles between various
types of antidepressants observed in short-term studies are
confirmed. In addition, as compared to SSRI treatment,
venlafaxine was associated with more profuse sweating.
Weight gain is associated with female gender and longer
duration of use. Other specific SEs are associated with
antidepressant dose and depression severity. Although pro-
longed antidepressant use is weakly associated with less SE
reporting, clinicians should be aware that antidepressant-
induced SEs are persistent. SEs should, therefore, be
incorporated in the evaluation of ongoing antidepressant
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